{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 148,
  "pageCount": 239,
  "prevPage": 147,
  "nextPage": 149,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses a combination of internal research claims and external clinical literature to expose a contradiction in the company's product claims.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/148",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-148",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Our research interviews suggest that Omnia is just a marketing ploy and stock promotion – “lipstick on a pig” according to one KOL.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-8267d4b150c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "Comparison of 10-kHz High-Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "042149a4-813e-4bec-a08a-cd16999f6584",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "paragraph",
      "text": "Our research interviews suggest that Omnia is just a marketing ploy and stock promotion – “lipstick on a pig” according to one KOL. Even Grossman apparently expected the “new” device to remain as mostly a high frequency product, according to former employees. Our research uncovered another reason which confirms that Omnia was never meant to be anything more than a high frequency device: its leads are still placed along specific vertebrae (T9/T10) which Nevro has always stipulated for high frequency stimulation. However, leads for low-frequency stimulation are typically placed at different points on the spine (T7/T8) based on trial-and-error via paresthesia mapping – ie, low frequency requires an entirely different type of surgical procedure, rendering the entire premise of Omnia clinically absurd. We note a paper by members of Nevro’s Scientific Advisory Board comparing lead placement for high vs. low frequency, as well as similar color from the publication for Nevro’s pivotal trial.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "539e9357-abfb-47eb-896d-39b6d2c7b688",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Lead position for HF10 therapy was based on extensive empirical observation that most patients respond to stimulation application near T9/10, while allowing for patient variation by covering T8-T11. For traditional low-frequency SCS, leads were placed at vertebral levels based on intraoperative paresthesia mapping involving patient feedback, typically resulting in parallel lead tip placement at T7-T8.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1daff32-f4c5-413f-81fc-a33d40982762",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“lipstick on a pig” — one KOL.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-84513926714b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660894/pdf/pme0016-0934.pdf; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058646/pdf/neu-79-667.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7268d1fc-a636-406e-a35e-11ea9344bf4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "table",
      "text": "Comparison of HF10 SCS with traditional SCS table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd598829-2352-4537-9bf8-ea4b3c166b63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "10. The new Omnia stimulator, the centerpiece of Nevro’s turnaround hopes, is a Hail Mary and colossal flop",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28f71cc2-0f79-4c55-af97-a0a0cc3fe781",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7219e6c9-dfca-4b7a-bb55-d5ab7c98ae9b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "44d2482d-08cb-4060-af82-8c9840c5d1c4",
      "evidence": "The slide explicitly frames the product as a 'marketing ploy' and 'stock promotion' to expose a clinical contradiction.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}